Jenny Walsh

Jenny Walsh

Pharmaceutical Development Consultant and Director at Jenny Walsh Consulting Ltd

Guest Expert
About

Jenny Walsh has over 30 years’ experience in the Pharmaceutical and Consumer Healthcare Industry and has been an independent consultant specialising in the development of age-appropriate medicines for children since 2011. She has actively contributed to numerous global paediatric developments projects, including Paediatric Investigation Plans (PIPs) and Pediatric Study Plans (PSPs) as well as providing support to the World Health Organization (WHO).  

She is a founder member of and subject matter expert for the European Paediatric Formulation Initiative (EuPFI) where her main interests include paediatric administration devices (workstream lead), taste masking and taste/palatability assessment, age-appropriate formulations and patient acceptability, and excipients. She is also an advisor to “conect4children Stichting” (c4c-S) pan-European network and the Society for Paediatric Medicines & Healthcare Initiative (India).  

Jenny is a UK registered pharmacist with her Bachelor of Pharmacy awarded by the University of Wales Institute of Science and Technology Cardiff and her PhD in pharmaceutical drug delivery from the University of Nottingham.

 

Expertise & focus areas
Quotient Sciences Translational Pharmaceutics
Translational Pharmaceutics, Drug Product Optimization, First-in-Human, Human ADME

Translational Pharmaceutics® Integrated Drug Development Info Sheet

10 March 2025 Read More

Latest news from Quotient Sciences

More News
News & Announcements, Articles & Publications, Artificial Intelligence Andy Lewis on AI‑Enabled Formulation Design and Faster Speed to Clinic By: Andy Lewis
Read More
News & Announcements, Articles & Publications, Early Drug Development, Artificial Intelligence AI's Role in Fast-tracking Early Drug Development; Our ground breaking alliance with Intrepid Labs By: Andy Lewis
Read More
News & Announcements, Articles & Publications, Artificial Intelligence Building Trust in AI‑Enabled Formulation: Insights from Quotient Sciences and Intrepid Labs By: Andy Lewis
Read More